Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
CM313
Sort By
Newest First
Sign in
1 / 1
1 / 1
Antibody
Timberlyne Therapeutics Secures $180M Series A to Advance CM313, a Promising Anti-CD38 Antibody for High-Need Diseases.
Timberlyne Therapeutics
PR-01-25-NI-07
Jan 10, 2025
